Ipsogen has launched MapQuant Dx HER2 test. Developed on the MapQuant Dx microarray diagnostic platform, MapQuant Dx HER2 measures a set of HER2-amplified genes that correlate with HER2 protein expression. This new HER2 test provides reliable, intelligible and decisive information for pathologists, oncologists and patients.
UK NEQAS IMPROVES PATIENT CARE
We aim to improve patient care through monitoring the quality of tests and their reporting, in an independent manner and on a not-for-profit basis.
We are here to help ensure optimal quality in testing for the benefit of patients.
We believe that the result of tests should be:
Liverpool Arena and Convention Centre
31 March - 3 April, 2025
Rome, Italy
10-11 April, 2025
Jubilee Hotel and Conference Centre, Nottingham, UK
15 May, 2025
Royal College Of Physicians Of Edinburgh
15 May, 2025
RAF Museum, Hendon, London NW9 5LL
15 May, 2025
